AusBiotech investment summit heading for Melbourne
Australia Biotech Invest 2013, the largest life science investment meeting in Australia, will this year be held on 28 and 29 October at the Melbourne Convention and Exhibition Centre.
Coordinated by AusBiotech, the investment summit will offer a platform for Australian life science companies to showcase themselves for investment and partnership opportunities.
Focused networking events with short presentations, one-on-one meetings and associated networking activities will allow investors to gain the information they need to make informed decisions. In addition, expert keynote presenters and investor panels will speak on the state of the global biotech investment environment and future growth markets.
The event will attract local and international decision-makers from the investment community including venture capitalists, private equity firms and investment bankers, as well as from governments.
Traditionally, the investment summit has been held at the same location as AusBiotech’s national biotechnology conference; however, this year the summit will be held in conjunction with Beacon’s Money and Mines event in Melbourne.
Beacon and AusBiotech have also partnered to deliver biotechnology investor meetings in Hong Kong.
The Acting Chief Executive Officer of AusBiotech, Glenn Cross, said having a standalone investment summit and partnering with Beacon will create a week-long investment mega-event.
“Australia Biotech Invest 2013 will lift the profile of the Australian biotechnology industry and create access to greater funding sources,” he said.
Independent research by Insync Surveys has shown the value of deals that were done as a result of the 2009 to 2010 events was at a minimum of $33 million, and this is expected to dramatically rise.
“The significant value generated clearly demonstrates the positive contribution that the investment summits have on the Australian biotech industry,” said Cross.
For further information, contact Hayley Laing, Investment Program Manager, AusBiotech, at hlaing@ausbiotech.org or 03 9828 1435.
Oxytocin analogue treats chronic abdominal pain
Researchers have developed a new class of oral painkillers to suppress chronic abdominal pain,...
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...
